While most known drugs impact the RAS-MAPK signaling pathways, our analysis could highlight the potential for RIOK1 inhibition as a feasible therapeutic target for MSI-High CRC tumors (Figure 4). This evidence concerns the gene RIOK1 and colorectal carcinoma.